{"id":"subcutaneous-apomorphine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Dyskinesia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL3187985","moleculeType":"Small molecule","molecularWeight":"625.59"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Apomorphine acts as a non-selective dopamine receptor agonist, primarily binding to D1 and D2 dopamine receptors. In Parkinson's disease, dopamine-producing neurons degenerate, leading to motor dysfunction; apomorphine bypasses this deficit by directly activating dopamine receptors. The subcutaneous formulation provides rapid onset of action, making it particularly useful for acute motor fluctuations and 'off' episodes in advanced Parkinson's disease patients.","oneSentence":"Subcutaneous apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to rapidly relieve motor symptoms of Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:39.775Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute motor fluctuations ('off' episodes) in advanced Parkinson's disease"}]},"trialDetails":[{"nctId":"NCT07257861","phase":"","title":"Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2026-02-02","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT07422675","phase":"PHASE1","title":"SAD Study in Patients With Parkinson's Disease and Motor Fluctuations","status":"RECRUITING","sponsor":"Serina Therapeutics","startDate":"2026-02-01","conditions":"PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease","enrollment":40},{"nctId":"NCT06954428","phase":"PHASE1","title":"Clinical Trial of Intranasal Delivery of NT-301","status":"COMPLETED","sponsor":"Nano PharmaSolutions Australia","startDate":"2025-06-20","conditions":"Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray","enrollment":49},{"nctId":"NCT01432821","phase":"NA","title":"Blinking and Yawning in Epilepsy: The Role of Dopamine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-09","conditions":"Idiopathic Generalized Epilepsy","enrollment":31},{"nctId":"NCT07219927","phase":"","title":"Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2025-03-31","conditions":"Parkinson Disease","enrollment":120},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT04887467","phase":"PHASE4","title":"Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2021-09-16","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT05213169","phase":"PHASE2, PHASE3","title":"Apomorphine in Severe Brain-injured Patients","status":"RECRUITING","sponsor":"University of Liege","startDate":"2021-06-18","conditions":"Disorder of Consciousness","enrollment":48},{"nctId":"NCT06080399","phase":"","title":"Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-02-15","conditions":"Parkinson Disease","enrollment":70},{"nctId":"NCT02940912","phase":"PHASE4","title":"Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Clinique Beau Soleil","startDate":"2017-01-31","conditions":"Parkinson Disease","enrollment":45},{"nctId":"NCT02230930","phase":"PHASE2","title":"Treatment of Apomorphine-induced Skin Reactions: a Pilot Study","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2015-06","conditions":"Parkinson's Disease, Apomorphine-induced Skin Reactions","enrollment":13},{"nctId":"NCT05405998","phase":"NA","title":"Development of a Proactive Health Care Pathway When Initiating Continuous Subcutaneous Apomorphine Infusion in Patients With Parkinson Disease : Impact on Their Autonomy (AUTAP)","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2022-12-01","conditions":"Parkinson Disease","enrollment":90},{"nctId":"NCT03391882","phase":"PHASE3","title":"A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2018-12-19","conditions":"Motor OFF Episodes Associated With Parkinson's Disease","enrollment":113},{"nctId":"NCT03623828","phase":"PHASE2","title":"Treating Severe Brain-injured Patients With Apomorphine","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2018-10-03","conditions":"Disorder of Consciousness","enrollment":8},{"nctId":"NCT04441697","phase":"","title":"Sleepiness in Parkinson's Patients With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2020-06-01","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT04786158","phase":"","title":"Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2018-12-01","conditions":"Progressive Supranuclear Palsy, Corticobasal Degeneration","enrollment":7},{"nctId":"NCT03292016","phase":"PHASE2","title":"A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by \"OFF\" Episodes","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-08-22","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT02006121","phase":"PHASE3","title":"Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2014-03-03","conditions":"Parkinson's Disease","enrollment":107},{"nctId":"NCT00489255","phase":"PHASE4","title":"Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2007-05","conditions":"Parkinson's Disease","enrollment":117},{"nctId":"NCT03793491","phase":"","title":"Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2018-12-18","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT00758368","phase":"PHASE2","title":"Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease","status":"WITHDRAWN","sponsor":"Oregon Health and Science University","startDate":"2009-03","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02702076","phase":"PHASE2","title":"Apomorphine in Parkinson's Disease Patients With Visual Hallucinations","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2017-05","conditions":"Parkinson's Disease, Hallucinations, Visual","enrollment":35},{"nctId":"NCT00761228","phase":"PHASE2","title":"Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury","status":"SUSPENDED","sponsor":"NeuroHealing Pharmaceuticals Inc.","startDate":"2010-07","conditions":"Brain Injury","enrollment":76},{"nctId":"NCT00955318","phase":"PHASE3","title":"Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-07","conditions":"Parkinson's Disease","enrollment":58},{"nctId":"NCT01063621","phase":"PHASE3","title":"Extended Long-Term Safety Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT01058291","phase":"PHASE3","title":"Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT00524914","phase":"NA","title":"Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2007-09","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00200512","phase":"PHASE2, PHASE3","title":"Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"1999-09","conditions":"Parkinson Disease","enrollment":16},{"nctId":"NCT00142545","phase":"PHASE3","title":"Long Term Safety and Efficacy of SC Apomorphine in Treatment of \"Off\" Episodes in Late-Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"1999-07","conditions":"Parkinson Disease","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":370,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["APO-go®"],"phase":"phase_3","status":"active","brandName":"subcutaneous apomorphine","genericName":"subcutaneous apomorphine","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Subcutaneous apomorphine is a dopamine agonist that stimulates dopamine receptors in the brain to rapidly relieve motor symptoms of Parkinson's disease. Used for Acute motor fluctuations ('off' episodes) in advanced Parkinson's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}